TEOC Oncologia Clínica Practice Questions - TEOC - Título De Especialista Em Oncologia Clínica (Sociedade Brasileira De Oncologia Clínica AMB) Exam

Access More Questions

A 48-year-old woman with cT2 cN1 HER2-positive (IHC 3+, ER/PR negative) invasive ductal carcinoma completes neoadjuvant chemotherapy consisting of 6 cycles of docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP). She undergoes lumpectomy and sentinel node biopsy. Histopathology shows a 1.4 cm residual invasive tumor with 2 positive lymph nodes (ypT1c ypN1a). According to the KATHERINE trial, what is the most appropriate adjuvant systemic therapy?

Trastuzumab plus pertuzumab to complete 1 full year of dual HER2 blockade Trastuzumab emtansine (T-DM1) 3.6 mg/kg intravenously every 3 weeks for 14 cycles Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously every 3 weeks for 14 cycles Dose-dense AC chemotherapy followed by adjuvant trastuzumab

Correct Answer:

Trastuzumab emtansine (T-DM1) 3.6 mg/kg intravenously every 3 weeks for 14 cycles

Access more questions from this quiz

Continue to TEOC Oncologia Clínica Practice Questions - TEOC - Título de Especialista em Oncologia Clínica (Sociedade Brasileira de Oncologia Clínica AMB) Exam for more practice questions and the full quiz experience.

Access More Questions